Assessing the effectiveness and cost‐effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease

Abstract

Prophylaxis can reduce bleeding frequency but requires more clotting factor than treatment on demand. More detailed proof of cost-effectiveness is likely to require the use of modelling techniques.